Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CYCLAFEM 7/7/7 vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive. Ethinyl estradiol suppresses gonadotropin release (FSH, LH) via negative feedback on hypothalamic-pituitary axis; norethindrone induces endometrial changes that inhibit implantation and thickens cervical mucus.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Prevention of pregnancy (FDA-labeled),Treatment of moderate acne vulgaris in women ≥15 years (FDA-labeled for some triphasic formulations),Off-label: dysmenorrhea, endometriosis-associated pain, menstrual irregularity
Prevention of pregnancy
One tablet (norethindrone 0.5 mg/ethinyl estradiol 35 mcg) orally once daily for 7 days, then one tablet (norethindrone 0.75 mg/ethinyl estradiol 35 mcg) orally once daily for 7 days, then one tablet (norethindrone 1 mg/ethinyl estradiol 35 mcg) orally once daily for 7 days. Dispensed in a 21-tablet pack with 7 placebo tablets. For contraception, take one tablet daily at same time each day for 28 days; begin next pack after 28-day cycle.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Terminal half-life: 5-13 hours (mean 8 hrs); clinical context: supports every-28-day dosing interval for intramuscular depot.
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Primarily hepatic via CYP3A4 hydroxylation and conjugation; ethinyl estradiol undergoes first-pass metabolism and enterohepatic recirculation. Norethindrone is metabolized to various reduced and conjugated metabolites.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Renal: ~50-60% as conjugated metabolites; Fecal: ~30-40% via bile; <1% unchanged.
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
~97-99% bound, primarily to sex hormone-binding globulin (SHBG) and albumin.
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
2.5-4.5 L/kg; extensive tissue distribution including adipose tissue, brain, and reproductive organs.
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: ~100% (combination with ethinyl estradiol enhances absorption); IM: 100% (depot formulation).
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (GFR <30 m L/min); use is not recommended due to potential hormonal accumulation and increased thrombotic risk.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Contraindicated in acute or chronic hepatic dysfunction (Child-Pugh class B or C) due to impaired metabolism of estrogen and progestin. For mild hepatic impairment (Child-Pugh class A), limited data; use alternative contraception if possible.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Safety and efficacy not established in females younger than 18 years for contraception; however, postmenarchal adolescents may use standard adult dosing (after menarche). Weight-based dosing not applicable; use weight ≥45 kg with no dose adjustment. For other indications (e.g., acne), follow adult dosing in patients ≥15 years.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Not indicated for postmenopausal women (age >55 years) as no contraceptive benefit. If used off-label, no specific dose adjustment; however, consider increased risk of cardiovascular events (thrombosis, hypertension, stroke) and metabolic effects (glucose intolerance, lipid changes) in older women with additional risk factors. Use lowest effective dose if necessary.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Cigarette smoking increases risk of serious cardiovascular events (myocardial infarction, thromboembolism, stroke) from combination oral contraceptive use, especially in women >35 years and those who smoke ≥15 cigarettes/day.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Thromboembolic disorders (DVT, PE, stroke, MI) – discontinue if symptoms occur,Hepatic disease (jaundice, hepatitis, cholestasis) – discontinue if develops,Hypertension – monitor blood pressure; discontinue if uncontrolled,Gallbladder disease – increased risk of cholelithiasis,Carbohydrate/lipid metabolism – monitor in diabetic or hyperlipidemic patients,Headache (including migraine) – discontinue if new or worsening,Uterine bleeding – rule out pregnancy if amenorrhea occurs,Depression – discontinue if severe,Ocular lesions (retinal thrombosis) – discontinue if visual disturbances occur
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Smoking >15 cigarettes/day and age ≥35 years,History of DVT/PE or thromboembolic disorders,Cerebrovascular or coronary artery disease,Uncontrolled hypertension,Diabetes with vascular involvement,Migraine with focal aura (especially if >35 years),Breast cancer (current or history),Estrogen-dependent neoplasia,Liver tumors (benign or malignant) or active liver disease,Pregnancy or suspected pregnancy,Undiagnosed abnormal uterine bleeding,Use of ritonavir-boosted protease inhibitors (CYP3A4 induction reduces efficacy)
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
No specific dietary restrictions are required. Grapefruit and grapefruit juice may modestly increase ethinyl estradiol levels, but this is not considered clinically relevant in most cases. Avoid excessive grapefruit intake to be cautious. The medication can be taken with or without food. High-fat meals may delay absorption of the hormones, but overall contraceptive efficacy is not affected.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
Pregnancy Category X. First trimester: Major birth defects including neural tube defects, cardiovascular malformations, and oral clefts. Second/third trimester: Fetal demasculinization in males, potential for feminization. Post-natal: Long-term reproductive tract abnormalities.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Excreted in breast milk. M/P ratio ~0.2. Avoid breastfeeding due to potential estrogenic effects on infant. Alternative methods recommended.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
Contraindicated in pregnancy. No dose adjustments applicable. Discontinue immediately if pregnancy occurs.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
Cyclafem 7/7/7 is a triphasic combined oral contraceptive containing ethinyl estradiol and norethindrone. The varying hormone doses across the three 7-day phases mimic the natural menstrual cycle. It is essential to start the first pack on the first day of menses for immediate contraceptive efficacy. Missed pills require specific instructions based on the week; if one pill is missed, take it as soon as remembered and continue. If two pills are missed in week 1 or 2, take two pills for two days, then resume. If two pills are missed in week 3, or three or more pills are missed at any time, use backup contraception for 7 days and consider starting a new pack. Breakthrough bleeding is common, especially in the first few cycles, and does not indicate contraceptive failure. Grapefruit juice may increase ethinyl estradiol levels, but clinical significance is minimal; still, avoid excessive intake.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take one pill daily at the same time each day, following the order of the pills in the pack (7 light yellow, 7 orange, 7 light green, then 7 white placebo).,If you miss a pill, refer to the package insert instructions based on how many pills you missed and the week you are in; use backup contraception if needed.,Common side effects include nausea, breast tenderness, and breakthrough bleeding, especially in the first 3 cycles; report severe symptoms.,Smoking increases the risk of serious cardiovascular side effects, especially in women over 35; do not smoke while on this medication.,Not all women can use combination oral contraceptives; inform your doctor if you have a history of blood clots, migraines with aura, liver disease, or certain cancers.,Use backup contraception (e.g., condoms) for the first 7 days if starting for the first time or after a break of more than 7 days.,Missed pills, vomiting, or diarrhea may reduce effectiveness; follow instructions for missed pills and use backup contraception.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CYCLAFEM 7/7/7 vs ALYACEN 1/35, answered by our medical review team.
CYCLAFEM 7/7/7 is a Oral Contraceptive that works by Combination estrogen-progestin contraceptive. Ethinyl estradiol suppresses gonadotropin release (FSH, LH) via negative feedback on hypothalamic-pituitary axis; norethindrone induces endometrial changes that inhibit implantation and thickens cervical mucus.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CYCLAFEM 7/7/7 and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CYCLAFEM 7/7/7 is: One tablet (norethindrone 0.5 mg/ethinyl estradiol 35 mcg) orally once daily for 7 days, then one tablet (norethindrone 0.75 mg/ethinyl estradiol 35 mcg) orally once daily for 7 days, then one tablet (norethindrone 1 mg/ethinyl estradiol 35 mcg) orally once daily for 7 days. Dispensed in a 21-tablet pack with 7 placebo tablets. For contraception, take one tablet daily at same time each day for 28 days; begin next pack after 28-day cycle.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CYCLAFEM 7/7/7 and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CYCLAFEM 7/7/7 is classified as Category C. Pregnancy Category X. First trimester: Major birth defects including neural tube defects, cardiovascular malformations, and oral clefts. Second/third trimester: Fetal demasculiniza. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.